journal article·2018-07

Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination

Robin Augustine, Dana Levin Ashkenazi, Roni Sverdlov Arzi, Vita Zlobin, Rona Shofti, Alejandro Sosnik

Acta Biomaterialia· Volume 74
Publisher page

Abstract

Nanonizationhas been extensively investigated to increase theoral bioavailability of hydrophobicdrugsin general andantiretrovirals(ARVs)used inthe therapy of the human immunodeficiency virus (HIV) infection in particular. Weanticipatedthatin the caseofprotease inhibitors, a family of pH-dependent ARVsthatdisplay high aqueous solubility undertheacidconditionsof thestomach andextremely low solubilityunder the neutral ones ofthe small intestine, this strategy might failowing to an uncontrolled dissolution-re-precipitation process that will take place along the gastrointestinal tract.To tackle thisbiopharmaceutical challenge, in this work, wedesigned, produced and fully characterized a novelNanoparticle-in-MicroparticleDelivery System(NiMDS)comprised of pure nanoparticlesofthefirst-line protease inhibitor darunavir(DRV) and itsboosting agentritonavir (RIT) encapsulated within film-coated microparticles.For this, a clinically relevant combination of pure DRV and RIT nanoparticles wassynthesized by a sequential nanoprecipitation/solvent diffusion and evaporation method employing sodium alginateas viscosity stabilizer. Then, pure nanoparticles were encapsulated within calcium alginate/chitosanmicroparticlesthat were film-coated with a series ofpoly(methacrylate) copolymers with differential solubility in the gastrointestinal tract. This coating ensured full stability under gastric-like pH and sustained drug release under intestinal one. PharmacokineticstudiesconductedinalbinoSpragueDawleyratsshowed that DRV/RIT-loadedNiMDSs containing 17% w/w drug loading based on dry weight significantlyincreasedthe oral bioavailabilityof DRVby 2.3-foldwith respect to both theunprocessedandthenanonized DRV/RIT combinations that showed statistically similar performance. Moreover, they highlighted the limited advantage of only drugnanonizationto improve the oral pharmacokinetics of protease inhibitors and the potential of our novel delivery approach to improve the oral pharmacokinetics of nanonized poorly water-soluble drugs displaying pH-dependent solubility. Statement of significance Protease inhibitors (PIs) are gold-standard drugs in many ARV cocktails. Darunavir (DRV) is the latest approved PI and it is included in the 20th WHO Model List of Essential Medicines. PIs poorly-water soluble at intestinal pH and more soluble under gastric conditions. Drug nanonization represents one of the most common nanotechnology strategies to increase dissolution rate of hydrophobic drugs and thus, their oral bioavailability. For instance, pure drug nanosuspensions became the most clinically relevant nanoformulation. However, according to the physicochemical properties of PIs, nanonization does not appear as a very beneficial strategy due to the fast dissolution rate anticipated under the acid conditions of the stomach and their uncontrolled recrystallization and precipitation in the small intestine that might result in the formation of particles of unpredictable size and structure (e.g., crystallinity and polymorphism) and consequently, unknown dissolution rate and bioavailability. In this work, we developed a sequential nanoprecipitation method for the production of pure nanoparticles of DRV and its boosting agent ritonavir in a clinically relevant 8:1 wt ratio using alginate as viscosity stabilizer and used this nanosuspension to produce a novel kind of nanoparticle-in-microparticle delivery system that was fully characterized and the pharmacokinetics assessed in rats. The most significant points of the current manuscript are.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: HIV/AIDS drug development and treatment · Advanced Drug Delivery Systems · HIV-related health complications and treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (59)

Show source-provided references
1. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy10.1073/pnas.0903107106 ↗
2. Protein and Peptide drug delivery: oral approaches10.4103/0250-474X.42967 ↗
3. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS10.1021/acs.jmedchem.5b01697 ↗
4. HIV protease inhibitors: a review of molecular selectivity and toxicity
5. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro10.1080/00498250110085845 ↗
6. Cobicistat versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences10.1177/1060028017717018 ↗
7. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection10.1007/s40265-013-0160-x ↗
8. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications10.1093/jac/dkw032 ↗
9. Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
10. Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy
11. Rationale and clinical utility of the darunavir– cobicistat combination in the treatment of HIV/AIDS
12. 20th WHO Model List of Essential Medicines and 6th WHO Model List of Essential Medicines for Children. http://www.who.int/medicines/publications/essentialmedicines/en/ (Accessed in April 2018).
13. Darunavir: in the treatment of HIV-1 infection10.2165/00003495-200767180-00010 ↗
14. Darunavir: a review of its use in the management of HIV-1 infection10.1007/s40265-013-0159-3 ↗
15. Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them10.1016/j.addr.2015.12.022 ↗
16. Clinical pharmacokinetics of darunavir10.2165/00003088-200746090-00002 ↗
17. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead10.1016/j.jconrel.2009.05.007 ↗
18. J. das Neves, B. Sarmento, A. Sosnik, Biomedical engineering approaches for HIV/AIDS prophylaxis, diagnostics and therapy, Adv. Drug Deliv. Rev. 103 (2016) 1–4.10.1016/j.addr.2016.06.010 ↗
19. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs10.1016/j.addr.2009.11.019 ↗
20. Progress in antiretroviral drug delivery using nanotechnology
21. T. Zhou,Z. Lin,P. Puligujja,D. Palandri,J. Hilaire,M. Araínga,et al., Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals, Nanomedicine (Lond.) 2018, in press. doi.org/10.2217/nnm-2017-038110.2217/nnm-2017-0381 ↗
22. Nanocrystal technology, drug delivery and clinical applications
23. Microfluidic nanoprecipitation systems for preparing pure drug or polymeric drug loaded nanoparticles: an overview10.1080/17425247.2016.1193151 ↗
24. Predicting intestinal precipitation-A case example for a basic BCS class II drug10.1007/s11095-010-0213-8 ↗
25. Evaluation of the use of Classical Nucleation Theory for predicting intestinal crystalline precipitation of two weakly basic BSC class II drugs10.1016/j.ejps.2013.12.004 ↗
26. Novel protease inhibitor-loaded Nanoparticle-in-Microparticle Delivery System leads to a dramatic improvement of the oral pharmacokinetics in dogs10.1016/j.biomaterials.2014.10.026 ↗
27. J. Guan, Y. Zhang, Q. Liu, X. Zhang, R. Chokshi, S. Mao, Exploration of alginates as potential stabilizers of nanosuspension, AAPS PharmSciTech 18 (2017) Art. 8.10.1208/s12249-017-0801-6 ↗
28. Efficacy and safety of darunavir / ritonavir versus lopinavir / ritonavir in ARV treatment-naïve HIV-1-infected patients at Week 4810.1097/QAD.0b013e32830285fb ↗
29. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments10.1211/jpp.60.1.0008 ↗
30. Gastrointestinal pH measurement in rats: influence of the microbial flora, diet and fasting10.1258/002367787781268693 ↗
31. The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors10.1248/bpb.30.1947 ↗
32. Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs10.1081/DDC-120030422 ↗
33. Alginate microparticles as oral colon drug delivery device: a review10.1016/j.carbpol.2017.03.033 ↗
34. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan - a review10.1016/j.jconrel.2006.04.017 ↗
35. Alginate: properties and biomedical applications10.1016/j.progpolymsci.2011.06.003 ↗
36. A. Sosnik, Alginate particles for oral drug delivery applications: State-of-the-Art, ISRN Pharm 2014 (2014) Art. ID926157.10.1155/2014/926157 ↗
37. Microencapsulation of lipophilic drugs in chitosan-coated alginate microspheres10.1016/S0378-5173(99)00173-8 ↗
38. Alginate in Drug Delivery Systems10.1081/DDC-120003853 ↗
39. Eudragit®: a technology evaluation10.1517/17425247.2013.736962 ↗
40. Development of extended release coevaporates and coprecipitates of promethazine HCl with acrylic polymers: formulation considerations10.1248/cpb.56.504 ↗
41. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit® L100–55 and Eudragit® S100 combinations10.1016/S0168-3659(98)00151-5 ↗
42. Nano-Precipitation: Preparation and Application in the Field of Pharmacy10.2174/1381612822666160408151702 ↗
43. The effect of particle size distribution on effective zeta-potential by use of the sedimentation method10.1016/j.apt.2015.01.017 ↗
44. Self-aggregation behaviour of novel thiosemicarbazone drug candidates with potential antiviral activity10.1039/c0nj00061b ↗
45. Solid state characterization of the anti-HIV drug TMC114: Interconversion of amorphous TMC114, TMC114 ethanolate and hydrate10.1016/j.ejps.2009.09.013 ↗
46. Nanoparticle technology for the delivery of poorly water-soluble drugs
47. Collapse, shrinkage and structural changes in dried alginate gels containing fillers10.1016/S0268-005X(01)00071-6 ↗
48. Preparation and characterization of drug-loaded polymethacrylate microspheres by an emulsion solvent evaporation method10.1080/0265204021000022770 ↗
49. Iron oxide induced enhancement of mucoadhesive potential of Eudragit® RLPO: formulation, evaluation and optimization of mucoadhesive drug delivery system10.1517/17425247.2013.790361 ↗
50. Eudragit® S-100 entrapped chitosan microspheres of valdecoxib for colon cancer10.1007/s10856-010-4109-2 ↗
51. Measurement of the swelling force in ionic polymeric networks: II. Swelling force and disintegration of controlled release dosage formulations using pH-sensitive components10.1016/0378-5173(94)00395-L ↗
52. Studies on the pH-dependent swelling properties and morphologies of chitosan/calcium-alginate complexed beads10.1002/macp.1997.021980925 ↗
53. Y.N. Dai, P. Li, J.P. Zhang, A.Q. Wang, Q. Wei, Swelling characteristics and drug delivery properties of nifedipine-loaded pH sensitive alginate-chitosan hydrogel beads, J. Biomed. Mater. Res. - Part B Appl. Biomater. 86 (2008) 493–500.10.1002/jbm.b.31046 ↗
54. Investigation of alginate beads for gastro-intestinal functionality, Part 1: In vitro characterisation10.1016/j.foodhyd.2008.04.011 ↗
55. Direct injection HILIC-MS/MS analysis of darunavir in rat plasma applying supported liquid extraction10.1016/j.jpha.2014.05.001 ↗
56. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats10.1016/S0278-6915(00)00136-8 ↗
57. Mucus Gel Thickness and Turnover in the Gastrointestinal Tract of the Rat: Response to Cholinergic Stimulus and Implication for mucoadhesion10.1023/A:1018961204325 ↗
58. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals10.1002/bdd.2510160502 ↗
59. Use of the domestic pig as a model for oral bioavailability and pharmacokinetic studies10.1002/bdd.2510150408 ↗